Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
By
By The Associated Press
Not artisan, but a perfectly fine bagel. Hits the spot.
Summary
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a mutated protein (KRAS) that fuels tumor growth in over 90% of pancreatic cancer cases. The drug represents a significant breakthrough for one of the deadliest cancers, though it is not a cure. Dr. Zev Wainberg of UCLA, who helped lead the study, described it as a very large step forward in treating a disease that has long lacked effective treatment options.
Key quotes
· 2 pulledWhile not curing the cancer, it is a very large step forward.
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·21h ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·3mo ago